United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - betamethasone valerate - cutaneous cream - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - adapalene, quantity: 1 mg/g - cream - excipient ingredients: propyl hydroxybenzoate; carbomer 934p; methyl hydroxybenzoate; cyclomethicone; squalane; sodium hydroxide; purified water; disodium edetate; methyl glucose sesquistearate; phenoxyethanol; peg-20 methyl glucose sesquistearate; glycerol - differin topical cream 0.1% is indicated for the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - adapalene, quantity: 1 mg/g - gel - excipient ingredients: propylene glycol; methyl hydroxybenzoate; poloxamer; phenoxyethanol; disodium edetate; purified water; carbomer 940; sodium hydroxide - for the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - betamethasone valerate - cutaneous cream - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

manx healthcare ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - benzoyl peroxide, quantity: 50 mg/g; clindamycin phosphate, quantity: 11.9 mg/g (equivalent: clindamycin, qty 10 mg/g) - gel - excipient ingredients: silicon dioxide; purified water; glycerol; sodium hydroxide; disodium lauril sulfosuccinate; dimeticone 100; carbomer 980; poloxamer; disodium edetate - for the topical treatment of comedo, papules and pustular acne vulgaris.

Israel - English - Ministry of Health

j-c health care ltd - ustekinumab - solution for injection - ustekinumab 45 mg / 0.5 ml - ustekinumab - * pque poriasis stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus u.v (puva).* psoriatic arthritisstelara, alone or in combination with mtx, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (dmard) therapy has been inadequatepediatric plaque psoriasis:stelara is indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* crohn’s disease:stelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.